Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.54 |
| ▸ | CHRNG | P07510 | 1/20 | 0.54 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.54 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747070 | 1.00 | HPGD (0.61) | HPGDKDM4CCA1CA2GPR139 | |
| SCHEMBL8802537 | 0.86 | HPGD (0.59) | HPGDGPR139NPC1LMNARAB9A | |
| SCHEMBL22151090 | 0.86 | HPGD (0.59) | HPGDGPR139NPC1LMNARAB9A | |
| SCHEMBL5448808 | 0.85 | HPGD (0.70) | HPGDGPR139NPC1LMNARAB9A | |
| SCHEMBL7399516 | 0.84 | HPGD (0.66) | HPGDGPR139NPC1LMNARAB9A | |
| SCHEMBL23213654 | 0.83 | GRN (0.64) | KDM4CCA1CA2GPR139 | |
| SCHEMBL31360685 | 0.83 | GRN (0.64) | KDM4CCA1CA2GPR139 | |
| SCHEMBL23213655 | 0.83 | GRN (0.64) | KDM4CCA1CA2GPR139 | |
| SCHEMBL13753410 | 0.82 | HPGD (0.62) | HPGDGPR139NPC1LMNARAB9A | |
| SCHEMBL12443252 | 0.81 | GPR139 (0.74) | HPGDGPR139NPC1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-3423467-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-28 | — | — | EP | disclosed |
| EP-3423467-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-28 | — | — | EP | disclosed |
| EP-3423467-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2019-01-09 | — | — | EP | disclosed |
| US-20180371015-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2018-12-27 | — | — | US | disclosed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| US-9757375-B2 | Compounds that inhibit human DNA ligases and methods of treating cancer | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-12 | — | — | US | disclosed |
| EP-2471774-B1 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-11-05 | — | — | US | disclosed |
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-03 | — | — | US | disclosed |
| US-7601844-B2 | Piperidinyl derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| EP-2049486-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2009-04-22 | — | — | EP | disclosed |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2007092681-A2 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-08-16 | — | — | WO | disclosed |
| EP-0842923-B1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU CO LTD (JP) | 2006-03-01 | — | — | EP | disclosed |
| CN-1349796-A | Pyrrole derivatives and medicine composition | NIPPON SHINYAKU CO LTD (JP) | 2002-05-22 | — | — | CN | disclosed |
| US-6172102-B1 | POLLAKIURIA OR URINARY INCONTINENCE | NIPPON SHINYAKU CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-5998459-A | INCOTINENCE THERAPY | NIPPON SHINYAKU CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0842923-A1 | PYRROLE DERIVATIVES AND MEDICINAL COMPOSITION | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1998-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298833-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | HPGD 1384/4885KDM4C 3970/4885CA1 1698/4885 |
| US-11059858-B2 | Difluoroketamide derivatives as HtrA1 inhibitors | HTRA1, HTR1A, HTR1E | HPGD 2751/4885KDM4C 3791/4885CA1 4300/4885 |
| US-20070208056-A1 | PIPERIDINYL DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCR1, CCR2, CCR3 | HPGD 1384/4885KDM4C 3970/4885CA1 1698/4885 |
| US-20150313898-A1 | COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER | LIG1, LIG4, LIG3 | HPGD 2256/4885KDM4C 1501/4885CA1 4627/4885 |
| US-20180371015-A1 | NEW DIFLUOROKETAMIDE DERIVATIVES AS HTRA1 INHIBITORS | HTRA1, HTR1A, HTR1E | HPGD 2838/4885KDM4C 3792/4885CA1 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.